Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Urban dwellers at greater risk of late-stage cancer

People who live in urban areas are more likely to develop late-stage cancer than those who live in suburban and rural areas. That is the conclusion of a new study published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

12 May 2009

Statins can lower PSA levels in men with prostate cancer

Beyond lowering cholesterol, statin medications have been found to have numerous other health benefits, including lowering a healthy man's risk of developing advanced prostate cancer, as well as lowering his prostate-specific antigen (PSA) levels.

30 Apr 2009

A potentially better option to blocks tumors

On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially better option.

30 Apr 2009

Experimental immunotherapy significantly prolongs survival in men with advanced prostate cancer

Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.

29 Apr 2009

$Prostate cancer therapy increases risk of fractures and cardiovascular-related death$

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009

Green nanotechnology from tea

Researchers from the University of Missouri-Columbia report in the Journal of Materials Chemistry that chemicals in tea are the best yet discovered to make consistent, biologically safe gold nanoparticles. More importantly, these gold nanoparticles show promising anticancer properties.

27 Apr 2009

Combination of vitamin E, selenium and soy does not prevent prostate cancer

The combination therapy of vitamin E, selenium and soy does not prevent the progression from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer, according to the new research presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

Cholesterol-lowering drugs may reduce inflammation in prostate tumors

Cholesterol-lowering drugs called statins may reduce inflammation in prostate tumors, possibly hindering cancer growth, according to a study led by investigators in the Duke Prostate Center.

26 Apr 2009

Cancer incidence, mortality, treatment and survival in Ireland

Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report reveals.

26 Apr 2009

Expert panel on prostate cancer screening and prevention

The American Urological Association (AUA) will offer journalists the opportunity to hear from world-renowned experts about prostate cancer screening and prevention during a special expert panel session on April 27, 2009 at 12:15 p.m.

26 Apr 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence

The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less.

26 Apr 2009

Active surveillance can offer prostate cancer patients more individualized patient care

Active surveillance may be a viable option for some men, but reclassification of disease risk over time is imperative to ensure outcomes, according to researchers in Toronto, who will present these criteria during the 104th Annual Scientific Meeting of the American Urological Association (AUA).

26 Apr 2009

MRI: Effective tool for determining pathologic stage of prostate cancer

In patients with prostate cancer undergoing prostatectomy, MR imaging plays an important role in determining if the cancer is restricted to the prostate gland or if it has spread beyond the capsule, according to a study performed at the University of California, Los Angeles, Los Angeles, CA.

23 Apr 2009